4.6

CiteScore

2.2

Impact Factor
  • ISSN 1674-8301
  • CN 32-1810/R
Volume 32 Issue 3
Apr.  2018
Turn off MathJax
Article Contents
Yu-tuan Wu, Xin Li, Lin-jie Lu, Lu Gan, Wei Dai, Yan-ling Shi, Vishnu Prasad Adhikari, Kai-nan Wu, Ling-quan Kong. Effect of neoadjuvant chemotherapy on the expression of hormone receptors and Ki67 in Chinese breast cancer patients: A retrospective study of 525 patients[J]. The Journal of Biomedical Research, 2018, 32(3): 191-197. DOI: 10.7555/JBR.32.20170059
Citation: Yu-tuan Wu, Xin Li, Lin-jie Lu, Lu Gan, Wei Dai, Yan-ling Shi, Vishnu Prasad Adhikari, Kai-nan Wu, Ling-quan Kong. Effect of neoadjuvant chemotherapy on the expression of hormone receptors and Ki67 in Chinese breast cancer patients: A retrospective study of 525 patients[J]. The Journal of Biomedical Research, 2018, 32(3): 191-197. DOI: 10.7555/JBR.32.20170059

Effect of neoadjuvant chemotherapy on the expression of hormone receptors and Ki67 in Chinese breast cancer patients: A retrospective study of 525 patients

More Information
  • Received Date: June 13, 2017
  • Revised Date: January 05, 2018
  • This study was designed to investigate the effect of neoadjuvant chemotherapy on the expression of hormone receptors and Ki67 in Chinese female breast cancer patients. The expression of estrogen receptor (ER), progesterone receptor (PR) and Ki67 among 525 neoadjuvant chemotherapy cases was studied by immunohistochemistry. Differences between specimens made through preoperative core needle biopsy and excised tissue biopsy were observed. The positive rates of ER, PR and Ki67 in core needle biopsy and excised tissue biopsy were 65.3% and 63.2%, 51.0% and 42.6%, 65.6% and 43.4%, respectively. The expression of ER, PR and Ki67 in core needle biopsy and excised tissue biopsy had no statistically significant difference. However, after neoadjuvant chemotherapy, the discordance rates of ER, PR and Ki67 were 15.2% (79/521), 26.9% (140/520) and 44.8% (225/502), respectively. The ER, PR and Ki67 status changed from positive to negative in 7.5% (39/521), 13.3% (69/520) and 21.1% (106/502) of the patients, whereas ER, PR and Ki67 status changed from negative to positive in 7.7% (40/521), 13.6% (71/520) and 23.7% (119/502) of the patients, respectively. These results showed that the status of some biomarkers changes after neoadjuvant chemotherapy and biomarker status needs to be reexamined to optimize adjuvant systemic therapy and better prognosis assessment.
  • Cited by

    Periodical cited type(13)

    1. Bhattarai S, Rupji M, Chao HP, et al. Cell cycle traverse rate predicts long-term outcomes in a multi-institutional cohort of patients with triple-negative breast cancer. BJC Rep, 2024, 2(1): 87. DOI:10.1038/s44276-024-00097-z
    2. Wang M, Wei Z, Kong J, et al. Comprehensive evaluation of the relationship between biomarker profiles and neoadjuvant chemotherapy outcomes for breast cancer patients. Diagn Pathol, 2024, 19(1): 53. DOI:10.1186/s13000-024-01451-y
    3. Xu LY, Zhao J, Wang X, et al. Non-sentinel lymph node metastases risk factors in patients with breast cancer with one or two sentinel lymph node macro-metastases. Heliyon, 2023, 9(11): e21254. DOI:10.1016/j.heliyon.2023.e21254
    4. Vemuru S, Huang J, Colborn K, et al. Clinical implications of receptor conversions in breast cancer patients who have undergone neoadjuvant chemotherapy. Breast Cancer Res Treat, 2023, 200(2): 247-256. DOI:10.1007/s10549-023-06978-0
    5. He Y, Zhang J, Chen H, et al. Clinical significance and prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients. Front Surg, 2023, 9: 1037215. DOI:10.3389/fsurg.2022.1037215
    6. Vuhahula EA, Jumanne S, Yahaya J. Expression of Ki67 as detected by MIB-1 and its association with histopathological high-risk factors among patients with retinoblastoma tumour: a cross-sectional study. BMJ Open Ophthalmol, 2022, 7(1): e000984. DOI:10.1136/bmjophth-2022-000984
    7. Zhao F, Cai C, Liu M, et al. Identification of the lymph node metastasis-related automated breast volume scanning features for predicting axillary lymph node tumor burden of invasive breast cancer via a clinical prediction model. Front Endocrinol (Lausanne), 2022, 13: 881761. DOI:10.3389/fendo.2022.881761
    8. Candás G, García A, Ocampo MD, et al. Impact of immunohistochemical profile changes following neoadjuvant therapy in the treatment of breast cancer. Ecancermedicalscience, 2021, 15: 1162. DOI:10.3332/ecancer.2021.1162
    9. Zattarin E, Leporati R, Ligorio F, et al. Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications. Cells, 2020, 9(12): 2644. DOI:10.3390/cells9122644
    10. Rey-Vargas L, Mejía-Henao JC, Sanabria-Salas MC, et al. Effect of neoadjuvant therapy on breast cancer biomarker profile. BMC Cancer, 2020, 20(1): 675. DOI:10.1186/s12885-020-07179-4
    11. Xu W, Chen X, Deng F, et al. Predictors of Neoadjuvant Chemotherapy Response in Breast Cancer: A Review. Onco Targets Ther, 2020, 13: 5887-5899. DOI:10.2147/OTT.S253056
    12. Ding Y, Ding K, Qian H, et al. Impact on survival of estrogen receptor, progesterone receptor and Ki-67 expression discordance pre- and post-neoadjuvant chemotherapy in breast cancer. PLoS One, 2020, 15(4): e0231895. DOI:10.1371/journal.pone.0231895
    13. Ma H, Li L, Jia L, et al. POM121 is identified as a novel prognostic marker of oral squamous cell carcinoma. J Cancer, 2019, 10(19): 4473-4480. DOI:10.7150/jca.33368

    Other cited types(0)

Catalog

    Article Metrics

    Article views (3213) PDF downloads (275) Cited by(13)
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return